Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MGNX Stock Forecast 2026-2027
$3.46
Current Price
$219.92M
Market Cap
Buy 3
Hold 4
Sell 0
Wall St Analyst Ratings
Distance to MGNX Price Targets
+160.1%
To High Target of $9.00
+15.6%
To Median Target of $4.00
-42.2%
To Low Target of $2.00
MGNX Price Momentum
-0.3%
1 Week Change
+21.0%
1 Month Change
+174.6%
1 Year Change
+114.9%
Year-to-Date Change
-10.8%
From 52W High of $3.88
+210.3%
From 52W Low of $1.12
📊 TOP ANALYST CALLS
Did MGNX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if MacroGenics is one of their latest high-conviction picks.
Latest MGNX Stock Price Targets & Analyst Predictions
Based on our analysis of 16 Wall Street analysts, MGNX has a neutral consensus with a median price target of $4.00 (ranging from $2.00 to $9.00). The overall analyst rating is Buy (7.4/10). Currently trading at $3.46, the median forecast implies a 15.6% upside. This outlook is supported by 3 Buy, 4 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Mayank Mamtani at B. Riley Securities, projecting a 160.1% upside. Conversely, the most conservative target is provided by Robert Burns at HC Wainwright & Co., suggesting a 42.2% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MGNX Analyst Ratings
3
Buy
4
Hold
0
Sell
MGNX Price Target Range
Low
$2.00
Average
$4.00
High
$9.00
Current: $3.46
Latest MGNX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MGNX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 10, 2026 | B. Riley Securities | Mayank Mamtani | Buy | Upgrade | $9.00 |
| Mar 10, 2026 | Barclays | Etzer Darout | Overweight | Maintains | $4.00 |
| Nov 3, 2025 | HC Wainwright & Co. | Robert Burns | Neutral | Reiterates | $2.00 |
| Sep 17, 2025 | Barclays | Etzer Darout | Overweight | Assumes | $3.00 |
| Aug 15, 2025 | Leerink Partners | Outperform | Maintains | $5.00 | |
| May 20, 2025 | B. Riley Securities | Mayank Mamtani | Neutral | Maintains | $3.00 |
| May 14, 2025 | Stifel | Stephen Willey | Hold | Maintains | $5.00 |
| May 14, 2025 | Barclays | Peter Lawson | Overweight | Maintains | $3.00 |
| Mar 25, 2025 | HC Wainwright & Co. | Robert Burns | Neutral | Maintains | $2.00 |
| Nov 7, 2024 | JMP Securities | Silvan Tuerkcan | Market Perform | Downgrade | $N/A |
| Nov 6, 2024 | HC Wainwright & Co. | Robert Burns | Neutral | Reiterates | $4.00 |
| Sep 18, 2024 | HC Wainwright & Co. | Robert Burns | Neutral | Reiterates | $4.00 |
| Aug 21, 2024 | HC Wainwright & Co. | Robert Burns | Neutral | Reiterates | $4.00 |
| Aug 15, 2024 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $14.00 |
| Aug 7, 2024 | BMO Capital | Etzer Darout | Market Perform | Maintains | $5.00 |
| Aug 1, 2024 | HC Wainwright & Co. | Robert Burns | Neutral | Reiterates | $4.00 |
| Aug 1, 2024 | BTIG | Kaveri Pohlman | Neutral | Downgrade | $N/A |
| Jul 31, 2024 | Barclays | Peter Lawson | Overweight | Maintains | $8.00 |
| Jul 31, 2024 | B. Riley Securities | Mayank Mamtani | Neutral | Downgrade | $5.00 |
| Jul 31, 2024 | Guggenheim | Kelsey Goodwin | Neutral | Downgrade | $N/A |
Macrogenics Inc. (MGNX) Competitors
The following stocks are similar to MacroGenics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Macrogenics Inc. (MGNX) Financial Data
Macrogenics Inc. has a market capitalization of $219.92M with a P/E ratio of 25.3x. The company generates $149.50M in trailing twelve-month revenue with a -49.9% profit margin.
Revenue growth is +113.0% quarter-over-quarter, while maintaining an operating margin of -29.3% and return on equity of -86.9%.
Valuation Metrics
Market Cap
$219.92M
Enterprise Value
$66.75M
P/E Ratio
25.3x
PEG Ratio
-2.6x
Price/Sales
1.5x
Growth & Margins
Revenue Growth (YoY)
+113.0%
Gross Margin
+75.5%
Operating Margin
-29.3%
Net Margin
-49.9%
EPS Growth
+132.5%
Financial Health
Cash/Price Ratio
+86.4%
Current Ratio
5.1x
Debt/Equity
66.1x
ROE
-86.9%
ROA
-17.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Macrogenics Inc. (MGNX) Business Model
About Macrogenics Inc.
What They Do
Develops innovative protein-based cancer therapeutics.
Business Model
Macrogenics operates by discovering and engineering monoclonal antibodies and bispecific molecules that target proteins involved in cancer growth. It generates revenue through partnerships with other pharmaceutical companies and by advancing its own investigational and clinical programs, which focus on precision and targeted cancer therapies.
Additional Information
Founded in 2000 and headquartered in the United States, Macrogenics utilizes proprietary technology platforms like the DART platform to develop multispecific antibodies. Their work not only impacts the biopharmaceutical industry but also enhances personalized medicine approaches in oncology.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
341
CEO
Mr. Eric Blasius Risser
Country
United States
IPO Year
2013
Website
www.macrogenics.comMacrogenics Inc. (MGNX) Latest News & Analysis
Latest News
Quick Summary
MacroGenics (NASDAQ: MGNX) will resume enrollment in the Phase 2 LINNET study of lorigerlimab for gynecologic cancers, following FDA's removal of a partial clinical hold, with updates expected by mid-2026.
Why It Matters
The FDA lifting the hold on lorigerlimab's clinical study signals potential advancement in cancer treatment, which may boost MacroGenics' stock value and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
MacroGenics, Inc. (MGNX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
1 month ago
Quick Summary
MacroGenics, Inc. (MGNX) presented at the Barclays 28th Annual Global Healthcare Conference, providing updates on its business and pipeline developments.
Why It Matters
MacroGenics' presentation at a major healthcare conference may signal strategic direction, potential partnerships, or new developments, impacting investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures
1 month ago
Quick Summary
MacroGenics, Inc. (NASDAQ: MGNX) reported its 2025 financial results and provided updates on corporate progress and upcoming data disclosures for its cancer therapeutics pipeline.
Why It Matters
MacroGenics' corporate update and financial results signal its growth trajectory and upcoming data disclosures, which could impact stock performance and investor sentiment in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
MacroGenics (MGNX) reported a quarterly loss of $0.22 per share, better than the estimated loss of $0.42, and improved from a loss of $0.25 per share a year earlier.
Why It Matters
MacroGenics' smaller-than-expected loss indicates improving financial performance, potentially boosting investor confidence and impacting stock valuation positively.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
MacroGenics, Inc. (Nasdaq: MGNX) will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026, featuring a presentation by President and CEO Eric Risser.
Why It Matters
MacroGenics' participation in key investor conferences signals potential insights into its strategies and pipeline, which may influence stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The FDA has imposed a partial clinical hold on the LINNET study of lorigerlimab for gynecologic cancer.
Why It Matters
The FDA's partial clinical hold on the LINNET study may delay lorigerlimab's development, impacting the company's stock and potential market for this cancer treatment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About MGNX Stock
What is Macrogenics Inc.'s (MGNX) stock forecast for 2026?
Based on our analysis of 16 Wall Street analysts, Macrogenics Inc. (MGNX) has a median price target of $4.00. The highest price target is $9.00 and the lowest is $2.00.
Is MGNX stock a good investment in 2026?
According to current analyst ratings, MGNX has 3 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.46. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MGNX stock?
Wall Street analysts predict MGNX stock could reach $4.00 in the next 12 months. This represents a 15.6% increase from the current price of $3.46. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Macrogenics Inc.'s business model?
Macrogenics operates by discovering and engineering monoclonal antibodies and bispecific molecules that target proteins involved in cancer growth. It generates revenue through partnerships with other pharmaceutical companies and by advancing its own investigational and clinical programs, which focus on precision and targeted cancer therapies.
What is the highest forecasted price for MGNX Macrogenics Inc.?
The highest price target for MGNX is $9.00 from Mayank Mamtani at B. Riley Securities, which represents a 160.1% increase from the current price of $3.46.
What is the lowest forecasted price for MGNX Macrogenics Inc.?
The lowest price target for MGNX is $2.00 from Robert Burns at HC Wainwright & Co., which represents a -42.2% decrease from the current price of $3.46.
What is the overall MGNX consensus from analysts for Macrogenics Inc.?
The overall analyst consensus for MGNX is neutral. Out of 16 Wall Street analysts, 3 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $4.00.
How accurate are MGNX stock price projections?
Stock price projections, including those for Macrogenics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 20, 2026 3:20 AM UTC